A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

Summary

Phase I study of RO7119929 given orally to participants with unresectable advanced or metastatic primary liver cancers and other solid tumors with predominant liver involvement. The primary objective of the study is to explore the safety and to determine the maximum tolerated dose (MTD) and/or optimal biologic dose (OBD) of RO7119929 as single agent.

Timeline

Start

2020-07-16

Primary completion

2023-01-09

Completion

2023-01-09

Publications

• Yoo C, Fabregat-Franco C, Lin CC, Qvortrup C, Oh DY, Yau T, Kim HD, Castet F, Ponz Sarvise M, Hsu C, Rohrberg KS, Lichtenegger FS, Franjkovic I, Kratochwil NA, Bessa J, Rossmann E, Schwalie PC, Rieder N, Poschinger T, Sie CG, Dettling S, Schlenker R, Jiang T, Dai C, Yun H, Hall E, Yeo Te-Ying A, Hoves S, Cannarile MA, Schiff C, Sangro B. First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers. J Immunother Cancer. 2026 Mar 9;14(3):e012783. doi: 10.1136/jitc-2025-012783.

Drugs

Indications